Hematological malignancies encompass a diverse range of diseases, such as leukemia, lymphoma, and multiple myeloma, among others. Within the multidisciplinary treatment approach, radiation therapy ...
Dearbhla Mescal revealed that she was preparing to become an ’empty nester’ right around the time that she was diagnosed with ...
Current trial data suggest that many MCED tests demonstrate high specificity, often above 99% thereby reducing the likelihood of false positives ...
Hepta refractory multiple myeloma is marked by antigen loss, genomic complexity, and 12.8 month median survival in multi centre data.
Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...
Ameet Patel, MD, concludes by outlining strategies to overcome operational, financial, and payer challenges in delivering advanced multiple myeloma therapies.
Rheumatologist Dr Thomas Batty and haematologist Dr Emma Conway O'Brien describe a rational approach to investigating multifocal pain ...
Abstract: Multiple open-circuit (OC) faults have severely deteriorated the reliable operation of active neutral-point-clamped (ANPC) inverters. To achieve fast and accurate detection for multiple OC ...
Princeton, New Jersey Thursday, February 19, 2026, 11:00 Hrs [IST] ...
The NDA is supported by data from the EXCALIBER-RRMM trial, which evaluated the safety and efficacy of iberdomide, an investigational cereblon E3 ligase modulator.
A myeloma survivor in long remission shares how research, expert care and advocacy turned fear into hope as more patients ...
FDA accepts and grants priority review to Bristol Myers' NDA for iberdomide combo in relapsed or refractory multiple myeloma. A decision is due on Aug. 17, 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results